Novartis AG Has Up to $5 Billion Burning in Its Pocket for M&As

Novartis AG, Europe’s second-biggest drugmaker by sales, said it’s looking for acquisitions that cost between $2 billion and $5 billion to bolster its position in areas including cancer and the development of copycat medicines.

“If there were pipeline assets that were late-stage in either oncology or pharma, those would really be the bull’s eye,” Chief Executive Officer Joe Jimenez said in a phone interview Tuesday after the company reported a decline in third-quarter profit excluding some items. Assets that could strengthen its generics business are another target, he said. The company’s products include treatments for heart disease and skin conditions.

Back to news